Precision Rooted in Scientific Rigor
Bridging the gap between CRISPR discovery and high confidence validation.
Our Mission
At Countagen, we are a team of molecular biologists and biotechnologists dedicated to solving the most persistent bottlenecks in genome editing analysis. We believe that Quality Control should never be a choice between sensitivity and scalability.
LockSeq was engineered to remove the "Validation Wall"—the noise, dropouts, and amplification biases inherent in traditional PCR-based NGS assays—providing researchers with a high-fidelity molecular lock for their most critical R&D milestones.
The Team & Founding Heritage
Countagen was founded upon decades of breakthrough research into padlock probe chemistry and molecular diagnostics conducted at Karolinska Institutet and SciLifeLab.
The company is led by Felix Neumann, PhD (CEO) and Iván Hernández-Neuta, PhD (CSO). Together, they have transitioned the core technology from academic proof-of-concept into the LockSeq industrial validation platform, focusing on the rigorous NGS requirements of modern Cell and Gene Therapy (CGT) developers.
Founding Pioneers: Countagen's scientific foundation was established by a world-class founding team of pioneers in molecular tools:
-
Prof. Mats Nilsson: A primary inventor of padlock probe and rolling circle amplification (RCA) technologies and Professor at Stockholm University/SciLifeLab.
-
Malte Kühnemund, PhD: An expert in molecular diagnostic tool development and biotech entrepreneurship.
-
Mårten Winge: A veteran biotech executive with a proven track record in scaling high-impact life science platforms.
This combination of deep academic heritage and industrial focus ensures that Countagen remains at the cutting edge of precision genomics.
Location & Contact
Countagen AB
Solna, Stockholm County
Sweden
Located within the Karolinska Institutet / SciLifeLab biotech ecosystem.